{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:46Z","timestamp":1791316786798,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10555-024-10207-5","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:15:25Z","timestamp":1724458525000},"page":"1573-1578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lost at SCLC: a review of potential platinum sensitizers"],"prefix":"10.1007","volume":"43","author":[{"given":"Bryan","family":"Oronsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacer","family":"Abrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunle","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Caroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"issue":"10","key":"10207_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B., Reid, T. R., Oronsky, A., & Carter, C. A. (2017). What\u2019s new in SCLC? A review. Neoplasia., 19(10), 842\u2013847. https:\/\/doi.org\/10.1016\/j.neo.2017.07.007","journal-title":"Neoplasia."},{"issue":"5","key":"10207_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","volume":"30","author":"JM Hou","year":"2012","unstructured":"Hou, J. M., Krebs, M. G., Lancashire, L., et al. (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. Journal of Clinical Oncology, 30(5), 525\u2013532. https:\/\/doi.org\/10.1200\/JCO.2010.33.3716","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10207_CR3","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.esmoop.2021.100059","volume":"6","author":"M Torres-Dur\u00e1n","year":"2021","unstructured":"Torres-Dur\u00e1n, M., Curiel-Garc\u00eda, M. T., Ruano-Ravina, A., et al. (2021). Small-cell lung cancer in never-smokers. ESMO Open., 6(2), 100059. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100059","journal-title":"ESMO Open."},{"issue":"9","key":"10207_CR4","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.7150\/jca.75622","volume":"13","author":"B Oronsky","year":"2022","unstructured":"Oronsky, B., Abrouk, N., Caroen, S., Lybeck, M., Guo, X., Wang, X., Yu, Z., & Reid, T. (2022). A 2022 update on extensive stage small-cell lung cancer (SCLC). Journal of Cancer, 13(9), 2945\u20132953. https:\/\/doi.org\/10.7150\/jca.75622","journal-title":"Journal of Cancer"},{"issue":"12","key":"10207_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti, A. K. P., Loo, B. W., Bassetti, M., et al. (2021). Small cell lung cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(12), 1441\u20131464. https:\/\/doi.org\/10.6004\/jnccn.2021.0058","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"10","key":"10207_CR6","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.21037\/jtd.2020.03.79","volume":"12","author":"AK Gergen","year":"2020","unstructured":"Gergen, A. K., Scott, C. D., & Mitchell, J. D. (2020). Surgery for limited stage small cell lung cancer. Journal of Thoracic Disease, 12(10), 6291\u20136297. https:\/\/doi.org\/10.21037\/jtd.2020.03.79","journal-title":"Journal of Thoracic Disease"},{"issue":"2","key":"10207_CR7","doi-asserted-by":"publisher","first-page":"e052556","DOI":"10.1136\/bmjopen-2021-052556","volume":"13","author":"F Blackhall","year":"2023","unstructured":"Blackhall, F., Girard, N., Livartowski, A., et al. (2023). Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: A retrospective cohort study. British Medical Journal Open, 13(2), e052556. https:\/\/doi.org\/10.1136\/bmjopen-2021-052556","journal-title":"British Medical Journal Open"},{"issue":"6","key":"10207_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.21.01639","volume":"40","author":"JA Bogart","year":"2022","unstructured":"Bogart, J. A., Waqar, S. N., & Mix, M. D. (2022). Radiation and systemic therapy for limited-stage small-cell lung cancer. Journal of Clinical Oncology, 40(6), 661\u2013670. https:\/\/doi.org\/10.1200\/JCO.21.01639","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10207_CR9","doi-asserted-by":"publisher","first-page":"1002385","DOI":"10.3389\/fonc.2022.1002385","volume":"15","author":"R Rittberg","year":"2022","unstructured":"Rittberg, R., Leung, B., Al-Hashami, Z., et al. (2022). Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer. Frontiers in Oncology, 15(12), 1002385. https:\/\/doi.org\/10.3389\/fonc.2022.1002385","journal-title":"Frontiers in Oncology"},{"issue":"17","key":"10207_CR10","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1002\/cam4.4089","volume":"10","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto, R., Anderson, I., Medgyasszay, B., et al. (2021). Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Medicine, 10(17), 5748\u20135756. https:\/\/doi.org\/10.1002\/cam4.4089","journal-title":"Cancer Medicine"},{"key":"10207_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000486622","volume":"94","author":"R Kondo","year":"2018","unstructured":"Kondo, R., Watanabe, S., Shoji, S., et al. (2018). A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology, 94, 223\u2013232. https:\/\/doi.org\/10.1159\/000486622","journal-title":"Oncology"},{"issue":"22","key":"10207_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn, M. J., Cho, B. C., Felip, E., et al. (2023). Tarlatamab for patients with previously treated small cell lung cancer. New England Journal of Medicine, 389(22), 2063\u20132075. https:\/\/doi.org\/10.1056\/NEJMoa2307980","journal-title":"New England Journal of Medicine"},{"key":"10207_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2024.42.16_suppl.300","volume":"42","author":"SR Chandana","year":"2004","unstructured":"Chandana, S. R., Choudury, N. J., Dowlati, A., et al. (2004). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Journal Clinical Oncology, 42, 16. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.300","journal-title":"Journal Clinical Oncology"},{"issue":"13","key":"10207_CR14","doi-asserted-by":"publisher","first-page":"1204143","DOI":"10.3389\/fonc.2023.1204143","volume":"29","author":"B Oronsky","year":"2023","unstructured":"Oronsky, B., Takahashi, L., Gordon, R., Cabrales, P., Caroen, S., & Reid, T. (2023). RRx-001: A chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. Frontiers in Oncology, 29(13), 1204143. https:\/\/doi.org\/10.3389\/fonc.2023.1204143","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"10207_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-023-01838-z","volume":"83","author":"N Jayabalan","year":"2023","unstructured":"Jayabalan, N., Oronsky, B., Cabrales, P., et al. (2023). A review of RRx-001: A late-stage multiindication inhibitor of NLRP3 activation and chronic inflammation. Drugs, 83(5), 389\u2013402. https:\/\/doi.org\/10.1007\/s40265-023-01838-z","journal-title":"Drugs"},{"issue":"41","key":"10207_CR16","doi-asserted-by":"publisher","first-page":"43172","DOI":"10.18632\/oncotarget.6526","volume":"6","author":"H Zhao","year":"2015","unstructured":"Zhao, H., Ning, S., Scicinski, J., Oronsky, B., Knox, S. J., & Peehl, D. M. (2015). Epigenetic effects of RRx001: A possible unifying mechanism of anticancer activity. Oncotarget, 6(41), 43172\u201343181. https:\/\/doi.org\/10.18632\/oncotarget.6526","journal-title":"Oncotarget"},{"issue":"3","key":"10207_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41416-019-0504-8","volume":"121","author":"D Morgensztern","year":"2019","unstructured":"Morgensztern, D., Rose, M., Waqar, S. N., et al. (2019). RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. British Journal of Cancer, 121(3), 211\u2013217. https:\/\/doi.org\/10.1038\/s41416-019-0504-8","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10207_CR18","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(15)00089-3","volume":"16","author":"T Reid","year":"2015","unstructured":"Reid, T., Oronsky, B., Scicinski, J., et al. (2015). Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol, 16(9), 1133\u20131142. https:\/\/doi.org\/10.1016\/S1470-2045(15)00089-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"10207_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijrobp.2022.12.031","volume":"116","author":"M Bonomi","year":"2023","unstructured":"Bonomi, M., Blakaj, D. M., Kabarriti, R., et al. (2023). PREVLAR: Phase 2 a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics, 116(3), 551\u2013559. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.12.031","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10207_CR20","doi-asserted-by":"crossref","unstructured":"Johnson M, Awad M, Koyama T, et al. (2023, November). Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: A subgroup analysis of a phase 1\/2 study. In 2023 World Conference on Lung Cancer. OA05 antibody drug conjugates: The next tsunami, sunday, September 10, 2023 - 15:00 - 16:00| Vol. 18, Issue 11. Supplement, S54\u2013S55.","DOI":"10.1016\/j.jtho.2023.09.042"},{"issue":"5","key":"10207_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","volume":"80","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B., Caroen, S., Oronsky, A., et al. (2017). Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology, 80(5), 895\u2013907. https:\/\/doi.org\/10.1007\/s00280-017-3392-8","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10207_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg, S., Disler, C., & Perego, P. (2021). The rediscovery of platinum-based cancer therapy. Nature Reviews Cancer, 21(1), 37\u201350. https:\/\/doi.org\/10.1038\/s41568-020-00308-y","journal-title":"Nature Reviews Cancer"},{"issue":"6","key":"10207_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","volume":"34","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B., Ray, C. M., Spira, A. I., Trepel, J. B., Carter, C. A., & Cottrill, H. M. (2017). A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Medical Oncology, 34(6), 103. https:\/\/doi.org\/10.1007\/s12032-017-0960-z","journal-title":"Medical Oncology"},{"issue":"12","key":"10207_CR24","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog, B. H., Devarakonda, S., & Govindan, R. (2021). Overcoming chemotherapy resistance in SCLC. Journal of Thoracic Oncology, 16(12), 2002\u20132015. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.018","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10207_CR25","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41467-022-29517-9","volume":"13","author":"D Lissa","year":"2022","unstructured":"Lissa, D., Takahashi, N., Desai, P., et al. (2022). Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nature Communications, 13(1), 2023. https:\/\/doi.org\/10.1038\/s41467-022-29517-9","journal-title":"Nature Communications"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10207-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T17:10:49Z","timestamp":1731345049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10207-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10207"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10207-5","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BO, SC, TR are employed by EpicentRx LM, YS, XW, LZ, and NA are employed by SciClone Pharmaceuticals NA has no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}